Cellomatics Biosciences, a Nottingham-based preclinical contract research organisation (CRO), is carving out a strong reputation as a trusted partner in drug discovery and development. Since its founding in 2015, the company has specialised in bespoke, cell-based assays that support pharmaceutical and biotech clients across immuno-inflammation, respiratory, oncology, and ophthalmology. By leveraging advanced human in vitro models, Cellomatics delivers robust, data-driven insights that help de-risk decision making and accelerate R&D timelines.
Under the leadership of CEO Shailendra Singh, Cellomatics has expanded organically over nine years, now employing a multidisciplinary team of 25 scientists and professionals. The company combines deep expertise in cell biology with a collaborative, client-focused approach, serving more than 100 biotech and pharmaceutical partners worldwide, from Europe and North America to Asia and South America. Its solutions are designed for decision-makers across R&D, translational medicine, and clinical development, offering scientifically rigorous preclinical data packages to satisfy regulatory expectations and support investment readiness.
Recent milestones highlight the company’s agility and innovation. Cellomatics introduced INNOBEX™, its proprietary Blood-Brain Barrier model, alongside new commercial platforms in NASH and pulmonary fibrosis—tools that have already been adopted globally. The business also recorded a 124% increase in new orders between October 2024 and March 2025 compared with the previous year, signalling rapid growth. Its move to a standalone research site in 2022 tripled laboratory capacity, while new high-throughput systems boosted assay throughput five-fold.
The company’s collaborations underscore its strength as a partner. A long-term relationship with LoQus23 Therapeutics, for example, has evolved into an integrated collaboration covering lead compound optimisation and in vivo testing. Cellomatics’ responsiveness—ranging from reallocating internal resources to validating new assay protocols—has demonstrated its ability to balance scientific rigour with flexible resourcing.
Industry recognition has followed. Cellomatics was awarded the Queen’s Award for Enterprise: International Trade in 2022, received the Medilink Midlands Award for Export Achievement in 2024, and achieved ISO 9001:2015 certification in 2025. It has also been named a finalist in prestigious honours such as the OBN Award for Best CRO and the Scrip Award for Best Specialist CRO. Client satisfaction remains consistently high, with post-project surveys reporting above 90% positive feedback.
With a growing global footprint, a reputation for scientific excellence, and an expanding portfolio of proprietary platforms, Cellomatics Biosciences continues to strengthen its role as a partner of choice for biotech and pharmaceutical innovators worldwide.
#DrugDiscovery #PreclinicalResearch #Oncology #BiotechInnovation #Cellomatics